Evaluation of the efficiency and safety of imeglimin on insulin secretion ability and insulin sensitivity in the treatment of type 2 diabetes mellitus

Evaluation of the efficiency and safety of imeglimin on insulin secretion ability and insulin sensitivity in the treatment of type 2 diabetes mellitus - Evaluation of the efficacy and safety of imeglimin on insulin secretion ability and insulin sensitivity

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053150

Enrollment

Registered

2023-12-25

Start date

2023-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Active treatment of imeglimin 2000mg a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes patients

Exclusion criteria

Exclusion criteria: 1) eGFR<30 2) Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose and IRI are set to be measured at baseline,3,6,9,12 months	—

Secondary

Measure	Time frame
Body mass index (BMI),blood pressure,albumin creatinine ratio (ACR),lipid and liver function are set to be measured at baseline,3,6,9,12 months	—

Countries

Japan

Contacts

Public ContactSachiko Hattori

Foundation Health Medicine Association Tohto Clinic Department of Diabetes and Metabolism

s-hattori@kenkoigaku.or.jp03-3239-0301

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026